http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (7): 598-599.

• 【新闻】 • 上一篇    下一篇

北京大学杨振军教授团队在反义核酸结构修饰物的体内递送及肝癌治疗研究中取得连续进展

北京大学药学院 天然药物及仿生药物国家重点实验室   

  1. 北京大学药学院 天然药物及仿生药物国家重点实验室
  • 收稿日期:2023-07-13 修回日期:2023-07-13 接受日期:2023-07-13 出版日期:2023-07-31 发布日期:2023-08-07

The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center
  • Received:2023-07-13 Revised:2023-07-13 Accepted:2023-07-13 Online:2023-07-31 Published:2023-08-07

摘要:

2023年5月4日, 北京大学药学院天然药物及仿生药物全国重点实验室杨振军教授团队在《Molecular Therapy-Nucleic Acids》上发表题为“Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects”的研究论文。该研究提供了一种更高效且更长效的抗肝细胞癌(hepatocellular carcinoma, HCC)的ASO纳米制剂, 同时揭示了中性胞苷/阳离子混合脂质递送结构优化的ASO的功能和机制, 具有良好的临床应用潜力。

Abstract:

The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer.

Supporting: